GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai RAAS Blood Products Co 002252.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.91

-0.61%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥7.35bn

FY2016FY2025

Net income

CN¥1.58bn

FY2016FY2025

Free cash flow

−CN¥483.9m

FY2016FY2025

Shareholders' equity

CN¥32.46bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥7.35bnCN¥8.18bnCN¥7.96bnCN¥6.57bnCN¥4.29bnCN¥2.76bnCN¥2.58bnCN¥1.80bnCN¥1.93bnCN¥2.33bn
Gross profitCN¥2.75bnCN¥3.30bnCN¥3.23bnCN¥2.89bnCN¥2.22bnCN¥1.70bnCN¥1.65bnCN¥1.19bnCN¥1.22bnCN¥1.48bn
Research and developmentCN¥223.4mCN¥250.9mCN¥173.7mCN¥145.7mCN¥129.0mCN¥129.7mCN¥102.4mCN¥96.2mCN¥96.9mCN¥76.7m
Operating incomeCN¥1.91bnCN¥2.68bnCN¥2.23bnCN¥2.28bnCN¥1.55bnCN¥1.50bnCN¥735.9mCN¥434.5mCN¥1.01bnCN¥1.95bn
Net incomeCN¥1.58bnCN¥2.19bnCN¥1.78bnCN¥1.88bnCN¥1.29bnCN¥1.32bnCN¥607.9m−CN¥1.52bnCN¥835.8mCN¥1.61bn
Diluted earnings per share0.240.330.270.280.190.200.13-0.310.170.33

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥37.80bnCN¥33.63bnCN¥31.93bnCN¥30.46bnCN¥27.24bnCN¥25.49bnCN¥11.85bnCN¥11.40bnCN¥14.46bnCN¥13.23bn
Cash and short-term investmentsCN¥2.11bnCN¥4.63bnCN¥4.20bnCN¥4.22bnCN¥2.96bnCN¥2.21bnCN¥1.73bnCN¥1.19bnCN¥4.52bnCN¥4.24bn
Total liabilitiesCN¥5.34bnCN¥1.69bnCN¥2.28bnCN¥1.64bnCN¥1.33bnCN¥363.7mCN¥362.0mCN¥496.6mCN¥1.98bnCN¥1.50bn
Debt—CN¥23.7mCN¥2.0mCN¥3.8mCN¥8.2mCN¥8.0m—CN¥150.0mCN¥360.0mCN¥384.0m
Shareholders' equityCN¥32.46bnCN¥31.93bnCN¥29.63bnCN¥28.82bnCN¥25.90bnCN¥25.12bnCN¥11.48bnCN¥10.89bnCN¥12.46bnCN¥11.71bn
Shares outstanding6,589m6,646m6,605m6,741m6,729m6,760m4,824m4,952m4,921m4,957m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−CN¥104.9m−CN¥482.1mCN¥2.28bnCN¥1.73bnCN¥1.29bnCN¥1.17bnCN¥872.7mCN¥262.5mCN¥268.8mCN¥638.2m
Capital spending−CN¥379.0m−CN¥407.1m−CN¥450.8m−CN¥225.7m−CN¥204.6m−CN¥251.8m−CN¥154.8m−CN¥156.9m−CN¥157.8m−CN¥147.5m
Free cash flow−CN¥483.9m−CN¥889.2mCN¥1.83bnCN¥1.50bnCN¥1.09bnCN¥917.1mCN¥717.9mCN¥105.6mCN¥110.9mCN¥490.7m
Dividends paid−CN¥317.9m−CN¥439.9m−CN¥202.2m−CN¥188.7m−CN¥168.5m−CN¥67.8m−CN¥1.6m−CN¥166.6m−CN¥218.4m−CN¥172.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.70bnCN¥1.51bnCN¥1.26bnCN¥2.14bnCN¥1.95bnCN¥2.01bnCN¥1.86bnCN¥2.06bn
Gross profitCN¥559.6mCN¥566.7mCN¥460.9mCN¥770.0mCN¥694.3mCN¥777.2mCN¥738.3mCN¥835.1m
Operating incomeCN¥270.3mCN¥326.7mCN¥157.0mCN¥434.3mCN¥549.4mCN¥675.2mCN¥420.5mCN¥712.4m
Net incomeCN¥345.4mCN¥315.8mCN¥106.3mCN¥440.8mCN¥463.8mCN¥566.1mCN¥355.5mCN¥597.0m
Diluted earnings per share0.050.050.020.070.070.090.050.09
Cash from operations——−CN¥843.0m−CN¥30.0m−CN¥36.0mCN¥775.0m−CN¥782.0mCN¥563.0m
Capital spending−CN¥78.0m−CN¥139.0m−CN¥171.0m−CN¥86.0m−CN¥58.0m−CN¥62.0m−CN¥84.0m−CN¥113.0m
Free cash flow——−CN¥1.01bn−CN¥116.0m−CN¥94.0mCN¥713.0m−CN¥866.0mCN¥450.0m
Total assetsCN¥37.46bnCN¥37.98bnCN¥37.78bnCN¥38.02bnCN¥38.14bnCN¥34.68bnCN¥33.63bnCN¥33.36bn
Cash and short-term investments——CN¥2.11bnCN¥2.10bnCN¥3.97bnCN¥4.04bnCN¥4.63bnCN¥3.71bn
DebtCN¥2.56bnCN¥2.55bnCN¥3.78bnCN¥583.1mCN¥2.87bnCN¥24.7m——
Shareholders' equityCN¥32.41bnCN¥32.52bnCN¥32.46bnCN¥32.58bnCN¥32.41bnCN¥32.50bnCN¥31.93bnCN¥31.16bn

Financial ratios

Data as of 19 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY2016
Gross margin37.4%40.4%40.5%44.0%51.7%61.6%———
Operating margin26.0%32.8%27.9%34.7%36.3%54.4%———
Net margin21.5%26.8%22.3%28.6%30.2%47.9%———
Return on equity4.9%6.9%6.0%6.5%5.0%5.3%———
Return on assets4.2%6.5%5.6%6.2%4.8%5.2%———
Free cash flow yield0.8%-0.2%8.4%5.9%4.5%4.3%———
Revenue growth-10.1%2.7%21.3%53.2%55.3%6.8%———
Earnings growth-28.1%23.3%-5.4%45.2%-2.2%117.8%———
Current ratio3.64x5.60x3.86x5.22x5.26x15.18x———
Debt to equity0.12x0.00x———0.00x0.01x0.03x0.03x
Equity ratio85.9%94.9%92.8%94.6%95.1%98.5%———
Interest coverage42.91x2797.50x4860.11x8659.33x1253.10x2279.14x———
R&D as a share of sales3.0%3.1%2.2%2.2%3.0%4.7%———
Buybacks as a share of market value0.9%-0.6%2.0%-0.2%0.5%-40.1%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.8%21.6%13.8%
Operating income-5.7%5.0%1.0%
Net income-5.7%3.6%0.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin39.0%40.5%43.4%47.9%
Operating margin29.6%30.3%32.8%37.7%
Net margin24.3%24.7%27.1%27.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings26.421.929.722.735.537.858.9-26.1116.971.0
Price to sales5.75.96.66.510.718.113.822.050.749.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 10 Feb 2026.

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017
Paid in the year0.0150.0670.030.0280.0250.010.0170.03
  • 9-for-5 split · 28 Sept 2016
  • 2-for-1 split · 17 Sept 2015
  • 2-for-1 split · 25 Sept 2014
  • 9-for-5 split · 8 May 2012
  • 17-for-10 split · 19 Oct 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.